Jiang, Haiping http://orcid.org/0000-0001-7499-0383
Zheng, Yulong
Qian, Jiong
Mao, Chenyu
Xu, Xin
Li, Ning
Xiao, Cheng
Wang, Huan
Teng, Lisong
Zhou, Hui
Wang, Shuyan
Zhu, Donglei
Sun, Tao
Yu, Yingying
Guo, Wenying
Xu, Nong
Funding for this research was provided by:
Innovent Biologics, Inc
Eli Lilly and Company
National Health and Family Planning Commission Research Fund & Zhejiang Provincial Medical and Health Major Science and Technology Plan Project (KWJ-ZJ-1802)
Public Welfare Technology Application Research Project of Zhejiang Province (LGF20E030004)
Article History
Received: 25 May 2020
Accepted: 2 October 2020
First Online: 17 October 2020
Compliance with ethical standards
:
: HZ, SYW, and DLZ are employees of Innovent Biologics. TS, YYY, and WYG are staff of Hangzhou ImmuQuad Biotechnologies. The other authors declare no conflicts of interest.
: All study procedures in the study were performed based on ethical guidelines in each site.
: The clinical data by the data cutoff date on January 15, 2019 was previously reported at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO), May 26, 2019, Chicago, USA, Abstract e20546 [CitationRef removed].
: Written informed consent was obtained from all the patients participated in the study.